Altamira Announces Notice of Allowance from USPTO for Bentrio Nasal Spray Patent
Altamira Therapeutics (OTCQB:CYTOF) has received a Notice of Allowance from the USPTO for a patent application (#17/466,142) covering the composition of Bentrio®, their nasal spray for allergic rhinitis treatment and prevention. The patent, with a priority date of September 8, 2020, will protect Bentrio's proprietary formulation in the USA, which represents the largest market for OTC allergic rhinitis products.
The drug-free and preservative-free nasal spray has shown significant effectiveness in relieving classic nasal symptoms of allergic rhinitis, including congestion, sneezing, itching, rhinorrhea, and ocular symptoms. The company plans to expand product availability globally through partnerships in the consumer health sector.
Altamira Therapeutics (OTCQB:CYTOF) ha ricevuto un Avviso di Concessione dall'USPTO per una domanda di brevetto (#17/466,142) che copre la composizione di Bentrio®, il loro spray nasale per il trattamento e la prevenzione della rinite allergica. Il brevetto, con una data di priorità dell'8 settembre 2020, proteggerà la formulazione proprietaria di Bentrio negli Stati Uniti, che rappresenta il mercato più grande per i prodotti da banco per la rinite allergica.
Lo spray nasale privo di farmaci e conservanti ha dimostrato una notevole efficacia nel sollievo dei classici sintomi nasali della rinite allergica, inclusi congestione, starnuti, prurito, rinorrea e sintomi oculari. L'azienda prevede di espandere la disponibilità del prodotto a livello globale attraverso partnership nel settore della salute dei consumatori.
Altamira Therapeutics (OTCQB:CYTOF) ha recibido un Aviso de Concesión de la USPTO para una solicitud de patente (#17/466,142) que cubre la composición de Bentrio®, su spray nasal para el tratamiento y la prevención de la rinitis alérgica. La patente, con una fecha de prioridad del 8 de septiembre de 2020, protegerá la formulación patentada de Bentrio en los EE. UU., que representa el mercado más grande para productos de rinitis alérgica de venta libre.
El spray nasal libre de fármacos y conservantes ha demostrado una efectividad significativa en el alivio de los síntomas nasales clásicos de la rinitis alérgica, incluidos la congestión, los estornudos, la picazón, la rinorrea y los síntomas oculares. La empresa planea expandir la disponibilidad del producto a nivel mundial a través de asociaciones en el sector de la salud del consumidor.
알타미라 테라퓨틱스 (OTCQB:CYTOF)는 알레르기 비염 치료 및 예방을 위한 그들의 비강 스프레이 Bentrio®의 조성에 대한 특허 출원(#17/466,142)에 대해 USPTO로부터 허가 통지를 받았습니다. 2020년 9월 8일의 우선일자를 가진 이 특허는 미국에서 Bentrio의 독점 제형을 보호하며, 이는 OTC 알레르기 비염 제품의 가장 큰 시장을 나타냅니다.
약물과 방부제가 없는 이 비강 스프레이는 비염의 전형적인 비강 증상인 코막힘, 재채기, 가려움증, 콧물 및 안구 증상을 완화하는 데 상당한 효과를 보였습니다. 이 회사는 소비자 건강 분야의 파트너십을 통해 전 세계적으로 제품 가용성을 확장할 계획입니다.
Altamira Therapeutics (OTCQB:CYTOF) a reçu un Avis de Concession de l'USPTO pour une demande de brevet (#17/466,142) couvrant la composition de Bentrio®, leur spray nasal pour le traitement et la prévention de la rhinite allergique. Le brevet, avec une date de priorité du 8 septembre 2020, protégera la formulation propriétaire de Bentrio aux États-Unis, qui représente le plus grand marché pour les produits en vente libre contre la rhinite allergique.
Ce spray nasal sans médicament et sans conservateur a montré une efficacité significative dans le soulagement des symptômes nasaux classiques de la rhinite allergique, y compris la congestion, les éternuements, les démangeaisons, la rhinorrhée et les symptômes oculaires. L'entreprise prévoit d'élargir la disponibilité du produit à l'échelle mondiale grâce à des partenariats dans le secteur de la santé des consommateurs.
Altamira Therapeutics (OTCQB:CYTOF) hat eine Mitteilung über die Genehmigung von USPTO für einen Patentantrag (#17/466,142) erhalten, der die Zusammensetzung von Bentrio®, ihrem Nasenspray zur Behandlung und Vorbeugung von allergischer Rhinitis, abdeckt. Das Patent, mit einem Prioritätsdatum vom 8. September 2020, wird die proprietäre Formulierung von Bentrio in den USA schützen, die den größten Markt für rezeptfreie Produkte gegen allergische Rhinitis darstellt.
Das medikamenten- und konservierungsmittelfreie Nasenspray hat eine signifikante Wirksamkeit bei der Linderung der klassischen Nasensymptome der allergischen Rhinitis gezeigt, einschließlich Verstopfung, Niesen, Juckreiz, Rhinorrhoe und okulären Symptomen. Das Unternehmen plant, die Produktverfügbarkeit weltweit durch Partnerschaften im Bereich der Verbrauchergesundheit zu erweitern.
- Patent protection secured for key US market
- Drug-free formulation proven effective for multiple allergy symptoms
- Targeting world's largest OTC allergic rhinitis market
- None.
Hamilton, March 07, 2025 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (OTCQB:CYTOF) today announced that the U.S. Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for a patent (application #17/466,142) relating to the composition of Bentrio®, a nasal spray developed and commercialized by its affiliate Altamira Medica AG (“Medica”) for preventing or treating allergic rhinitis. The claims are directed to the key ingredients and composition of Bentrio’s proprietary formulation. The patent, upon issuance, will have an initial priority date of September 8, 2020, and is expected to provide key intellectual property protection for Bentrio in the USA, the world’s largest market for “over the counter (OTC)” products for allergic rhinitis relief and treatment.
“We are very pleased to have achieved this major milestone in the protection of our intellectual property around Bentrio,” commented Thomas Meyer, Altamira’s founder, Chairman, and CEO. “Based on a drug free and preservative free formulation, Bentrio has demonstrated significant alleviation of the classic nasal symptoms of allergic rhinitis, including congestion, sneezing, itching, and rhinorrhea as well as of ocular symptoms. We look forward to making the product available in more and more countries, and in particular also to allergy sufferers in North America, through well established partners in the consumer health space.”
About Bentrio
Bentrio is an “over the counter” drug-free nasal spray for personal protection against airborne allergens and, where approved, against airborne viruses. Upon application into the nose, Bentrio forms a protective gel layer on the nasal mucosa. This thin film is designed to prevent the contact of airborne particles with cells; in addition, the composition serves to bind such particles and help with their discharge. The efficacy and safety of Bentrio has been demonstrated in a total of four clinical trials, of which the largest one (“NASAR” study) enrolled 100 patients suffering from seasonal allergic rhinitis. In NASAR, participants self-administered either Bentrio or saline nasal spray for two weeks 3 x per day. The study showed a statistically significant reduction in the mean daily reflective Total Nasal Symptom Score (rTNSS) for Bentrio compared to saline (p = 0.013), as well as a statistically highly significant improvement in health-related quality of life (Rhinoconjunctivitis Quality of Life Questionnaire, p < 0.001) and superior global ratings of efficacy by patients and investigators alike (p < 0.001). In addition, Bentrio showed good safety and tolerability, similar to saline controls, and fewer Bentrio treated patients used relief medication and more of them enjoyed symptom-free days compared to saline treatment. For more information, visit: www.bentrio.com
About Altamira Therapeutics
Altamira Therapeutics (OTCQB:CYTOF) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (xPhore™ platform). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a
Forward-Looking Statements
This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include but are not limited to the clinical utility of Altamira’s product candidates, the timing or likelihood of regulatory filings and approvals, Altamira’s intellectual property position and Altamira’s financial position. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira’s Annual Report on Form 20-F for the year ended December 31, 2023, and in Altamira’s other filings with the Securities Exchange Commission (“SEC”), which are available free of charge on the SEC’s website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira or to persons acting on behalf of Altamira are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.
Investor Contact:
FAQ
What patent protection did Altamira (CYTOF) receive for Bentrio nasal spray?
What symptoms does Bentrio nasal spray treat according to Altamira (CYTOF)?
What are the key features of Bentrio's formulation by Altamira (CYTOF)?
What is Altamira's (CYTOF) commercialization strategy for Bentrio?
